Results 81 to 90 of about 787 (175)

Elewski et al. Supplementary data

, 2023
Supplementary material for the manuscript "Rapid and sustained improvements in GPPGA scores with spesolimab for treatment of generalized pustular psoriasis flares in the randomized, placebo-controlled Effisayil 1 study" by Boni Elewski et al ...
Parkinson, J (via Mendeley Data)
core   +1 more source

Cross-spectrum efficacy of spesolimab in IL-36-mediated dermatoses: a ′case study

Journal of Dermatological Treatment
Background The nosological distinction between acute generalized exanthematous pustulosis (AGEP) and generalized pustular psoriasis (GPP) has become increasingly unclear due to shared IL-36 pathway dysregulation.
RuoYan Tong, ChaoChao Chen, Ling Huang, ChangWen Ni   +3 more
doaj   +1 more source

What is ' chronic' pustular psoriasis? Identifying candidates for long-term subcutaneous spesolimab treatment

Recently, generalized pustular psoriasis (GPP) has been reclassified as a superficial neutrophilic dermatosis [1], with interleukin(IL)-36 identified as its major driver [2].
Francesca Prignano, Anna Balato, Gisondi, Paolo, Marzano, Angelo Valerio, Maronese, Carlo Alberto, Carlo Alberto Maronese, Annunziata Dattola, Prignano, Francesca, Maria Concetta Fargnoli, Balato, Anna, Costanzo, Antonio, Angelo Valerio Marzano, Stefano Piaserico, Dattola, Annunziata, Fargnoli, Maria Concetta, Piaserico, Stefano, Antonio Costanzo, Paolo Gisondi   +17 more
core   +1 more source

Nuevas estrategias terapéuticas en la psoriasis [PDF]

, 2023
La psoriasis es una afección dermatológica inflamatoria crónica, inmunomediada, caracterizada por la hiperproliferación de queratinocitos y lesiones eritematosas y descamativas. Hay alrededor de 60 millones de pacientes afectados en el mundo.
Frade Cerezales, Andrea
core  

Heterogeneous Response to Spesolimab in Pyoderma Gangrenosum Depends on Underlying Myeloid Disorders-supplymentary files

supplymentary files for brief report "Heterogeneous Response to Spesolimab in Pyoderma Gangrenosum Depends on Underlying Myeloid ...
wang, youcong
core   +1 more source

Real-world experience of spesolimab for generalized pustular psoriasis flares in adult patients: A multicenter retrospective study

Spesolimab is a novel interleukin-36 receptor inhibitor recently approved for treatment of generalized pustular psoriasis (GPP). While clinical trials have evaluated its efficacy and safety for this indication, real-world evidence (RWE) is sparse. Herein,
Sood, S (via Mendeley Data), Sood, Siddhartha   +1 more
core   +1 more source

Generalized pustular psoriasis successfully treated with spesolimab: A case report [PDF]

Generalized pustular psoriasis is defined as a primary, sterile, macroscopically visible pustular eruption on non-acral skin, which can occur with or without systemic inflammation and/or psoriasis vulgaris, and can either be relapsing or be persistent ...
Francesco Bellinato, Giampiero Girolomoni, Noemi Brigenti, Paolo Gisondi   +3 more
core   +1 more source

Intralesional Spesolimab: A Novel and Effective Approach for Palmoplantar Pustulosis Treatment – A Case Report

International Medical Case Reports Journal
Si-Ning Wang,* Yi-Zhou Lu,* Yujuan Zhao, Wei Cao, Rui-Li Zhang Department of Dermatology, The Second Affiliated Hospital Nanjing Medical University, Nanjing Medical University, Nanjing, People’s Republic of China*These authors contributed ...
Wang SN, Lu YZ, Zhao Y, Cao W, Zhang RL
doaj  

New and Emerging Treatments for Generalized Pustular Psoriasis: Focus on IL-36 Receptor Inhibitors

Pharmaceutics
Generalized Pustular Psoriasis (GPP) is a rare and severe subtype of psoriasis that significantly impacts patients’ quality of life. Until recently, no specific treatment modalities were available, and treatment for GPP followed the guidelines for the ...
João Vilaça, Orhan Yilmaz, Tiago Torres   +2 more
doaj   +1 more source

Diagnosis, Screening and Treatment of Patients with Palmoplantar Pustulosis (PPP): A Review of Current Practices and Recommendations

Clinical, Cosmetic and Investigational Dermatology, 2020
Egídio Freitas,1 Maria Alexandra Rodrigues,1 Tiago Torres1,2 1Department of Dermatology, Centro Hospitalar e Universitário do Porto, Porto, Portugal; 2Instituto de Ciências Biomédicas Abel Salazar, Universidade do Porto, Porto,
Freitas E, Rodrigues MA, Torres T
doaj